Company: PRGO
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001585364-25-000014
Chunk: 109

Company: PERRIGO Co plc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 109
---
4 101.5 94.8 Digestive Health36.5 41.0 35.5 Other CSCI(2)97.3 125.4 102.2 Total CSCI1,679.6 1,693.3 1,525.7 Total net sales$4,373.4 $4,655.6 $4,451.6 (1)    We updated our global reporting product categories as a result of legacy sales being moved out of Other CSCA and into respective categories. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows.(2)    Consisted primarily of our Rare Diseases Business in CSCI and other miscellaneous or otherwise uncategorized product lines in CSCA and CSCI, none of which is greater than 10% of the segment net sales. While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $306.2 million, $337.3 million, and $350.1 million for the years ended December 31, 2024, December 31, 2023, and December 31, 2022, respectively.The following table provides information about contract assets from contracts with customers (in millions): Balance Sheet LocationDecember 31, 2024December 31, 2023Short-term contract assetsPrepaid expenses and other current assets$43.9 $28.5 

NOTE 3 - DIVESTITURES AND ACQUISITIONS

Divestitures During the Year Ended December 31, 2024Rare Diseases BusinessOn July 10, 2024, we completed the sale of our HRA Pharma Rare Diseases Business (the "Rare Diseases Business") to Esteve Healthcare S.L. ("ESTEVE") for total consideration of $244.5 million, inclusive of net cash received, an estimated working capital adjustment, and contingent consideration with a fair value of $34.5 million. 

75

Perrigo Company plc - Item 8 Note 3

The sale resulted in a pre-tax gain of $5.8 million, net of professional fees, recorded in Other (income) expense, net on the Consolid